Drug trial shows promise for cutting impact of outbreak of infection

News -

A new phase II clinical trial of the oral treatment Lynovex indicates the drug may work in conjunction with an existing standard therapy slow the worsening of infection in people with cystic fibrosis.

The CARE CF 1 clinical trial by Aberdeen-based pharmaceuticals company NovaBiotics compared various doses of Lynovex, a drug that combines mucus-thinning, anti-biotic and anti-biofilm properties, combined with a standard CF treatment, against the standard treatment with a placebo.

Early data from this phase II trial indicate that the combination was safe and appeared to reduce the impact of an outbreak of infection, called an exacerbation, and the related inflammation.

The coordinating investigator of CARE CF 1, Professor Graham Devereux said: “This trial suggests that people with CF who are exacerbating, feel and do better if Lynovex is added to their usual treatments.”

Dr Janet Allen, Director of Strategic Innovation at the Cystic Fibrosis Trust, which part-funded an earlier trial of the drug, commented:” The Cystic Fibrosis Trust has been following the progress of Lynovex during its development, including support for the first in man clinical trial. It’s a good news story that such collaboration can be fruitful.”

Full analysis of the trial data is currently in progress, after which the company hopes to progress to a larger phase III trial to fully assess the clinical effectiveness of Lynovex as an adjunct to the standard therapy.

Find out more about clinical trials and how to participate by exploring our Trials Tracker.

Explore trials

Your donation will make a difference:

Select amount